Torilidis Fructus Compound for Selective Cancer-Cell Cytotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anticancer drugs often target genes or proteins expressed in both cancer and normal cells, leading to severe side effects and impairing the quality of life for patients, while existing compositions using Torilidis Fructus extracts lack a specific compound with targeted anticancer efficacy.

Innovation Solution

A compound isolated from Torilidis Fructus, represented by Formula 1 or its pharmaceutically acceptable salts, is used as an active ingredient in an anticancer pharmaceutical composition, demonstrating selective cytotoxicity towards various cancer cells without affecting normal cells, and reducing tumor size and weight in animal models.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anticancer drugs are used to target cancer cells, then cancer treatment effectiveness is improved, but severe side effects occur due to killing normal cells as well

Engineering Contradiction:

Improveanticancer effectivenessVSAvoidside effects on normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by identifying and targeting specific molecular markers that are locally expressed in cancer cells but not in normal cells. The anticancer agent is designed to recognize and bind to these specific markers, enabling selective destruction of cancer cells while spares normal cells, thus resolving the contradiction between effectiveness and side effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses specific molecular markers as intermediaries between the anticancer agent and cancer cells. These markers serve as mediators that allow the drug to indirectly target and destroy cancer cells through a selective binding mechanism, avoiding direct harm to normal cells while maintaining treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Torilidis Fructus extract is used for anticancer treatment, then some anticancer activity is observed, but lack of specific compound isolation limits targeted efficacy

Engineering Contradiction:

Improveanticancer activityVSAvoidtargeted efficacy

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies the extraction principle by isolating and identifying specific active compounds from the Torilidis Fructus extract. This extraction process separates the useful anticancer components from the complex mixture, enabling targeted efficacy and improving manufacturing precision while maintaining the beneficial anticancer activity observed in the crude extract

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentEP4105196B1Compound isolated from torilidis fructus, and anticancer pharmaceutical composition containing same as active ingredient

Publication Date: 2025.11.05 PHARMA GEN CO LTD

Figure 1(A)~1(C)
Figure 2(A)~2(C)
Figure 3(A)~3(C)

AI summary

The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient. The compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.